20 January 2018 - 4 Shevat 5778 - ד' שבט ה' אלפים תשע"ח
Water-technology companies exhibit at Thai Water Expo E-mail

Leading Israeli water-technology companies exhibited in the Israel National Pavilion booth at the Thai Water Expo 2017 in Bangkok from 7 to 10 June.

Since its establishment in 1948, Israel has faced decades of water shortages, and has gained significant experience in developing unique solutions in intelligent water resource management, irrigation and desalination. Israel is now recognised as a world leader in these spheres.

The Israel National Pavilion at the Thai Water Expo showcased Israeli water-technology solutions and innovation, tailored especially for Thailand. The exhibition and conference included a wide range of seminars and events about such topics as water resource management, wastewater treatment and management, sewerage, irrigation and natural treatment systems. One of the seminars was titled “Treating, Managing and Creating Water – Israeli Innovative Solutions”.

Please login or register to see the full article
OurCrowd-India collaboration deal E-mail

Israeli equity crowdsourcing fund OurCrowd signed a strategic collaboration agreement with Indian wealth management company Reliance Private Client.

The agreement will allow Indian investors to access overseas venture capital funds on the OurCrowd platform and to invest in Israel’s dynamic startup ecosystem.

Under the terms of the deal, Reliance Private Client will offer its accredited clientele access to OurCrowd’s startup investment products and fund offerings. Indian investors will have the opportunity to invest via the platform in OurCrowd’s broad range of offerings, including OurCrowd Qure: Israel’s First Digital Health Fund and the OC50 Portfolio Index fund.

OurCrowd CEO Jon Medved said: “Historically, the greatest challenge for global investors has been access to highquality global alternate asset class investment opportunities, especially into early and growth stage companies based out of mature startup ecosystems such as Israel and Silicon Valley.”

He added: “This new deal structure will provide Indian investors access to quality VC deals through a trusted partner such as Reliance Private Client.”

Please login or register to see the full article
Israeli audio content platform attracts Japanese investment E-mail

In June, Israeli AI-powered (Artificial Intelligence–powered) audio content platform Audioburst announced the launch of its cross-platform API (Application Programme Interface), along with the completion of a US$6.7 million Series A financing round.

The round was led by Advanced Media Inc., a speech recognition technology company in Japan, with participation from additional investors, including Flint Capital, 2BAngels and the Mobileye consortium of investors.

Audioburst aims to change the way people consume audio content in a connected world by automating the process of indexing, organising and discovering audio segments in real time. Audioburst listens to millions of minutes of live and pre-recorded audio content each day, transforming it into searchable bursts wrapped with rich metadata.

Please login or register to see the full article
Catalyst CEL Fund invests in genetic drug development company Eloxx E-mail

Catalyst CEL Fund announced that it had invested in Eloxx Pharmaceuticals Limited, a clinical-stage company developing therapeutics for genetic diseases caused by so-called “nonsense” mutations. In the US$24 million investment round, Catalyst CEL Fund is one of the lead investors, together with Israeli life sciences venture capital fund Pontifax and other leading industry players.

Eloxx Pharmaceuticals is a biopharmaceutical company committed to treating patients suffering from rare genetic diseases caused by [jargon alert!] premature termination codons nonsense mutations. The company is focused on the discovery, development and commercialisation of compounds for the treatment of genetic diseases, including cystic fibrosis and cystinosis.

Yair Shamir, Managing Partner of Catalyst CEL Fund, said: “We believe that Eloxx is on track to become the innovative leader in the development of drugs addressing rare and ultrarare genetic diseases, based on the company’s unique abilities to restore full-length functional proteins in genetic diseases.”

Silvia Noiman, Founder and CEO of Eloxx said: “The company aims to initiate multiple clinical studies for ELX-02, our lead development candidate. Importantly, we anticipate achieving substantial clinical milestones over the course of 2017 and 2018, particularly in our lead clinical programs in cystic fibrosis and cystinosis patients carrying nonsense mutations.”

Please login or register to see the full article
Israeli and Japanese companies sign MOU on cyber know-how E-mail

Israel and Japan signed two co-operation agreements in May to enhance economic and industrial collaboration between the countries.

Israeli cyber companies will be involved in a new training programme led by the Japanese Ministry of Economy, Trade, and Industry for Japanese cyber companies. The programme involves the integration and assimilation of technologies and know-how from Israel.

In the framework of this co-operation, Israeli companies will present cyber risks to Japanese companies, while exposing them to systems developed in Israel for protection against such attacks.

The Japanese Minister of Economy, Trade, and Industry Hiroshige Seko and his Israeli counterpart, Eli Cohen, signed the agreements during the Japanese minister’s visit to Israel. “The agreement of understandings concerning cyberspace includes joint cyber exercises by companies from Israel and companies from Japan, an exchange of know-how and technologies in this field, and the possibility of integrating companies from Israel in cyber protection in Japan, especially in preparation for the 2020 Tokyo Olympics. The Japanese regard Israel as a pioneer in cyberspace, and they need us to help prepare for the Olympic Games,” said Dagan Alony of Israel’s Ministry of Economy and Industry Foreign Trade Administration.

Please login or register to see the full article
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Warning: Parameter 1 to modMainMenuHelper::buildXML() expected to be a reference, value given in /home/joomla789/domains/jewishtimesasia.org/public_html/libraries/joomla/cache/handler/callback.php on line 99
Jewish Times Asia is published by Jewish Times Asia Ltd. © Copyright 2018.
Material in the newspaper or on this site may not be used or reproduced in any form or in any way without permission from the editor.
While every effort has been made to ensure the content is true and accurate, the publisher is not responsible for any errors or omissions in the printed text.